Vicore Pharma Holding ABVCRE -7.54%13 EV-to-OCF is -95.25 as of Jul. 07, 2026. GuruFocus rates VCRE with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 1,408 Biotechnology companies, Vicore Pharma Holding AB ranks better than 61.36% on this metric.
The historical rank and industry rank for Vicore Pharma Holding AB's EV-to-OCF or its related term are showing as below:
VCRE'
s EV-to-OCF Range Over the Past 10 Years
Min: -109.8 Med: -7.64 Max: -1.58
Current: -95.25
During the past 13 years, the highest EV-to-OCF of Vicore Pharma Holding AB was -1.58. The lowest was -109.80. And the median was -7.64.
VCRE's EV-to-OCF is ranked better than 61.36% of 1408
companies
in the Biotechnology industry
Industry Median: -3.605
vs VCRE: -95.25
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vicore Pharma Holding AB (NAS:VCRE) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vicore Pharma Holding AB's PE Ratio (TTM) for today is calculated as:
Vicore Pharma Holding AB's share price for today is $15.025.
Vicore Pharma Holding AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.202.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vicore Pharma Holding AB EV-to-OCF Related Terms
Vicore Pharma Holding AB EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vicore Pharma Holding AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vicore Pharma Holding AB EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Vicore Pharma Holding AB's EV-to-OCF falls into.
Vicore Pharma Holding AB's current Enterprise Value is $4,120.01 Mil.
Vicore Pharma Holding AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vicore Pharma Holding AB (VCRE) has a EV-to-OCF of -95.25 as of Jul. 07, 2026. According to the industry distribution chart, Vicore Pharma Holding AB ranks #544 out of 1408 companies in the Biotechnology industry, placing it in the top 38.6%.
Is Vicore Pharma Holding AB's EV-to-OCF too high?
Vicore Pharma Holding AB's current EV-to-OCF is -95.25. Based on the distribution chart, Vicore Pharma Holding AB ranks #544 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vicore Pharma Holding AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's EV-to-OCF compare to ?
According to the Biotechnology industry distribution chart, Vicore Pharma Holding AB ranks #544 out of 1408 companies for EV-to-OCF. This puts Vicore Pharma Holding AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Vicore Pharma Holding AB's current EV-to-OCF is -95.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (VCRE) has a current EV-to-OCF of -95.25. The current EV-to-OCF is -95.25. Vicore Pharma Holding AB's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Vicore Pharma Holding AB (VCRE), the current EV-to-OCF is -95.25 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
13GF Score
Get the complete analysis for VCRE
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCRE has been successfully added to your 
